Johanna Mercier | President And Head Of U.S., France, Germany And Japan Commercial Markets
Bristol Myers Squibb

Johanna Mercier, President And Head Of U.S., France, Germany And Japan Commercial Markets, Bristol Myers Squibb

Johanna Mercier is President and Head of U.S. & France, Germany, Japan/Korea/Taiwan at Bristol-Myers Squibb, where she oversees a complex organization responsible for $17B in revenue annually, 80% of total company revenues.  In this leadership role, Johanna strives to instill a balance of innovation and accountability among the 4,500 employees working to deliver transformational medicines from the company’s oncology, cardiovascular, and immunoscience portfolios. Johanna is also actively engaged with the policy and advocacy community to ensure the affordability and access of prescription medicines to patients.

Johanna’s career at Bristol-Myers Squibb spans 25 years. After over a decade in sales and marketing in Canada, she went on to lead worldwide early and clinical portfolios followed by market teams across both the US and Europe.  As General Manager of UK & Ireland, Johanna achieved double digit growth while implementing a new operating model. As President of Worldwide Markets for Europe, Australia and Canada, she led international markets driving $4B in revenue and overseeing 1700 employees.  She successfully attained access and reimbursement in the region for the company’s immuno-oncology portfolio in highly cost-sensitive markets. She most recently led the US business and successfully evolved the culture and drove strong commercial execution with double digit growth and multiple launches that changed the standard of care in melanoma and renal cancers.

Johanna is a director on the Robert Wood Johnson University Hospital Board. She is a staunch advocate for diversity and inclusion and a sought-after mentor. Johanna holds a science degree from the University of Montreal, and an M.B.A. from Concordia University.


Immunotherapy Conference Day 2 @ 09:50

Panel discussion: Commercial strategies in immunotherapy

  • High level pharma companies come together to discuss their strategies for tackling cancer
last published: 19/Feb/19 10:05 GMT

back to speakers




To Sponsor Or Exhibit


Derek Cavanagh
t/ +44 (0)207 092 1297




To Speak


Joan Shutt
t/ +44 (0)207 092 1134




To Register


Tayyab Abbasi
t/ +44 (0)207 092 1210